1
|
Shmidt D, Mamonkin M. CAR T Cells in T Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA 2024:S2152-2650(24)00211-8. [PMID: 38955579 DOI: 10.1016/j.clml.2024.05.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/29/2024] [Accepted: 05/28/2024] [Indexed: 07/04/2024]
Abstract
Chimeric antigen receptor (CAR T) therapy produced excellent activity in patients with relapsed/refractory B-lineage malignancies. However, extending these therapies to T cell cancers requires overcoming unique challenges. In the recent years, multiple approaches have been developed in preclinical models and some were tested in clinical trials in patients with treatment-refractory T-cell malignanices with promising early results. Here, we review main hurdles impeding the success of CAR T therapy in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL), discuss potential solutions, and summarize recent progress in both preclinical and clinical development of CAR T therapy for these diseases.
Collapse
Affiliation(s)
- Daniil Shmidt
- Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX
| | - Maksim Mamonkin
- Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX.
| |
Collapse
|
2
|
Begna KH, Abdallah NH, Janania-Martinez M, Mangaonkar AA, Rangan A, Herrick JL, Gangat N. Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant. Haematologica 2024; 109:689-692. [PMID: 37706335 PMCID: PMC10828762 DOI: 10.3324/haematol.2023.283740] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2023] [Accepted: 09/07/2023] [Indexed: 09/15/2023] Open
Affiliation(s)
- Kebede H Begna
- Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester.
| | - Nadine H Abdallah
- Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester
| | | | | | - Aruna Rangan
- Department of Laboratory medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester
| | - Jennifer L Herrick
- Department of Laboratory medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester
| | - Naseema Gangat
- Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester
| |
Collapse
|
3
|
García‐Hernández V, Arambilet D, Guillén Y, Lobo‐Jarne T, Maqueda M, Gekas C, González J, Iglesias A, Vega‐García N, Sentís I, Trincado JL, Márquez‐López I, Heyn H, Camós M, Espinosa L, Bigas A. β-Catenin activity induces an RNA biosynthesis program promoting therapy resistance in T-cell acute lymphoblastic leukemia. EMBO Mol Med 2023; 15:e16554. [PMID: 36597789 PMCID: PMC9906382 DOI: 10.15252/emmm.202216554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Revised: 12/09/2022] [Accepted: 12/13/2022] [Indexed: 01/05/2023] Open
Abstract
Understanding the molecular mechanisms that contribute to the appearance of chemotherapy resistant cell populations is necessary to improve cancer treatment. We have now investigated the role of β-catenin/CTNNB1 in the evolution of T-cell Acute Lymphoblastic Leukemia (T-ALL) patients and its involvement in therapy resistance. We have identified a specific gene signature that is directly regulated by β-catenin, TCF/LEF factors and ZBTB33/Kaiso in T-ALL cell lines, which is highly and significantly represented in five out of six refractory patients from a cohort of 40 children with T-ALL. By subsequent refinement of this gene signature, we found that a subset of β-catenin target genes involved with RNA-processing function are sufficient to segregate T-ALL refractory patients in three independent cohorts. We demonstrate the implication of β-catenin in RNA and protein synthesis in T-ALL and provide in vitro and in vivo experimental evidence that β-catenin is crucial for the cellular response to chemotherapy, mainly in the cellular recovery phase after treatment. We propose that combination treatments involving chemotherapy plus β-catenin inhibitors will enhance chemotherapy response and prevent disease relapse in T-ALL patients.
Collapse
Affiliation(s)
- Violeta García‐Hernández
- Program in Cancer ResearchInstitut Hospital del Mar d'Investigacions Mèdiques (IMIM), CIBERONCBarcelonaSpain
| | - David Arambilet
- Program in Cancer ResearchInstitut Hospital del Mar d'Investigacions Mèdiques (IMIM), CIBERONCBarcelonaSpain
| | - Yolanda Guillén
- Program in Cancer ResearchInstitut Hospital del Mar d'Investigacions Mèdiques (IMIM), CIBERONCBarcelonaSpain
| | - Teresa Lobo‐Jarne
- Program in Cancer ResearchInstitut Hospital del Mar d'Investigacions Mèdiques (IMIM), CIBERONCBarcelonaSpain
| | - María Maqueda
- Program in Cancer ResearchInstitut Hospital del Mar d'Investigacions Mèdiques (IMIM), CIBERONCBarcelonaSpain
| | - Christos Gekas
- Program in Cancer ResearchInstitut Hospital del Mar d'Investigacions Mèdiques (IMIM), CIBERONCBarcelonaSpain
| | - Jessica González
- Program in Cancer ResearchInstitut Hospital del Mar d'Investigacions Mèdiques (IMIM), CIBERONCBarcelonaSpain
| | - Arnau Iglesias
- Program in Cancer ResearchInstitut Hospital del Mar d'Investigacions Mèdiques (IMIM), CIBERONCBarcelonaSpain
| | - Nerea Vega‐García
- Hematology LaboratoryHospital Sant Joan de Déu BarcelonaBarcelonaSpain,Developmental Tumor Biology Group, Leukemia and Other Pediatric HemopathiesInstitut de Recerca Sant Joan de Déu, CIBERERBarcelonaSpain
| | - Inés Sentís
- CNAG‐CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST)BarcelonaSpain
| | - Juan L Trincado
- CNAG‐CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST)BarcelonaSpain
| | - Ian Márquez‐López
- Program in Cancer ResearchInstitut Hospital del Mar d'Investigacions Mèdiques (IMIM), CIBERONCBarcelonaSpain
| | - Holger Heyn
- CNAG‐CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST)BarcelonaSpain,Universitat Pompeu Fabra (UPF)BarcelonaSpain
| | - Mireia Camós
- Hematology LaboratoryHospital Sant Joan de Déu BarcelonaBarcelonaSpain,Developmental Tumor Biology Group, Leukemia and Other Pediatric HemopathiesInstitut de Recerca Sant Joan de Déu, CIBERERBarcelonaSpain
| | - Lluis Espinosa
- Program in Cancer ResearchInstitut Hospital del Mar d'Investigacions Mèdiques (IMIM), CIBERONCBarcelonaSpain
| | - Anna Bigas
- Program in Cancer ResearchInstitut Hospital del Mar d'Investigacions Mèdiques (IMIM), CIBERONCBarcelonaSpain,Josep Carreras Leukemia Research Institute (IJC)BarcelonaSpain
| |
Collapse
|